טוען...
Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
PURPOSE: The purpose of our study is to report our experience with the use of certolizumab pegol in patients with refractory non-infectious uveitis. OBSERVATIONS: We present a case series of three patients with non-infectious uveitis, treated with twice-monthly subcutaneous certolizumab pegol. All o...
שמור ב:
| הוצא לאור ב: | Am J Ophthalmol Case Rep |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7068621/ https://ncbi.nlm.nih.gov/pubmed/32190782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajoc.2020.100633 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|